We are live on ! Find out more
RNAZ icon

TransCode Therapeutics
RNAZ

8 hedge funds and large institutions have $155K invested in TransCode Therapeutics in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.91% less ownership

Funds ownership: 3.65% → 1.73% (-1.9%)

11% less funds holding

Funds holding: 9 → 8 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

35% less capital invested

Capital invested by funds: $237K → $155K (-$82K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
8
Holders Change
-1
Holders Change %
-11.11%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DS
DRW Securities
Illinois
+$122K
2
Citigroup
Citigroup
New York
+$16.5K
3
FDCDDQ
Federation des caisses Desjardins du Quebec
Quebec, Canada
+$10.2K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$219K
2
UBS Group
UBS Group
Switzerland
-$11.2K
3
SC
SouthState Corp
Florida
-$3.76K
4
TRCT
Tower Research Capital (TRC)
New York
-$2.71K
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$23

RNAZ Hedge Fund Activity: Q3 2025 in Review

8 of the 7,643 institutional investors tracked by Wall St. Rank reported a position in TransCode Therapeutics (RNAZ) for Q3 2025, worth a combined $155K — down 35% from $237K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of RNAZ and 3 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.

The largest buyer was DRW Securities, opening a new position worth an estimated $122K. The largest seller was Goldman Sachs, exiting entirely with an estimated $219K sold.

  • 8 institutional investors held TransCode Therapeutics (RNAZ) as of Q3 2025, down from 9 in Q2 2025.
  • Funds reported $155K of TransCode Therapeutics stock for Q3 2025, down 35% quarter-over-quarter.
  • 3 funds opened new TransCode Therapeutics positions in Q3 2025 and 4 closed out, a net change of -1 holder.
  • The largest TransCode Therapeutics buyer in Q3 2025 was DRW Securities, an estimated $122K added.
  • The largest TransCode Therapeutics seller in Q3 2025 was Goldman Sachs, an estimated $219K sold.

Based on aggregated 13F filings for Q3 2025.